We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Glioma Risk Lower with Elevated Blood Sugar

By LabMedica International staff writers
Posted on 16 May 2017
Image: New research suggests that there may be a link between blood sugar and glioma (Photo courtesy of MNT).
Image: New research suggests that there may be a link between blood sugar and glioma (Photo courtesy of MNT).
While many cancers are more common among those with diabetes, cancerous brain tumors called gliomas are less common among those with elevated blood sugar and diabetes.

Glioma is a heterogeneous primary brain tumor for which there is no treatment that ensures long-term survival and patients diagnosed with the most common adult form of this tumor, glioblastoma, survive on average only 14 months.

An international team of scientists led by those at the Ohio State University evaluated blood sugar and diabetes data and its relationship to subsequent development of brain cancer and found that those with elevated blood sugar and diabetes had a lower risk of developing glioma. They used data from the Apolipoprotein MOrtality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (n = 269,365). They identified individuals who were followed for a maximum of 15 years after their first blood glucose test until glioma diagnosis, death, emigration or the end of follow-up.

They conducted an exploratory analysis of the 51 glioma cases using the Me-Can data set with multiple measurements to determine whether glucose values equal to or less than 7.0 mmol/L varied with the number of measurements or time between the blood glucose test and glioma diagnosis. They found that fasting and non-fasting glucose dose-response relationships were similar allowing them to combine data from these two groups.

They found that the relative proportions of male and female total glioma cases differ between the cohorts (in AMORIS 65% are men; in Me-Can 52%), as does fasting status (in AMORIS 61% of blood was drawn when total glioma cases were fasting; in Me-Can all blood samples were collected from fasting participants). Pre-diagnostic blood glucose levels were inversely related to glioma risk and pre-diagnostic diabetes. During the year before diagnosis, blood glucose was inversely associated with glioma in the AMORIS but not the Me-Can cohort. This AMORIS result is consistent with their hypothesis that excess glucose consumption by the preclinical tumor accounts for the inverse association between blood glucose and glioma.

Judith Schwartzbaum, PhD, a professor and lead author of the study said, “Diabetes and elevated blood sugar increase the risk of cancer at several sites including the colon, breast and bladder. But in this case, these rare malignant brain tumors are more common among people who have normal levels of blood glucose than those with high blood sugar or diabetes.” The study was published on May 3, 2017, in the journal Scientific Reports.

Gold Member
Automated MALDI-TOF MS System
EXS 3000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automatic Hematology Analyzer
DH-800 Series

Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
GLOBE SCIENTIFIC, LLC